In Brief: Perclose
This article was originally published in The Gray Sheet
Executive Summary
Perclose: Submits premarket approval application supplement to FDA for its Prostar Plus and Prostar XL next-generation surgical closure systems for arterial access sites. The submissions for the 8 Fr and 10 Fr Prostar Plus and 8 Fr Prostar XL follow the firm's April 30 PMA approval for the Prostar first-generation system ("The Gray Sheet" May 5, I&W-1). The supplement is supported by data from the 515-patient, seven-site Sutures to Ambulate and Discharge (STAND) II trial. Preliminary results disclosed in May indicated the Prostar Plus reduced the average length of patient hospitalization by 14% compared to conventional treatment ("The Gray Sheet" May 26, In Brief)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.